[93] Are claims for newer drugs for overactive bladder warranted?
Two previous Therapeutics Letters on drugs for overactive bladder (OAB) concluded that the antimuscarinic drugs (oxybutynin, tolterodine, darifenacin, solifenacin and trospium) had
This is a bimonthly publication targeting identified problematic therapeutic issues in a brief, simple and practical manner.
The process leading up to publication involves a rigorous, systematic literature review by different working groups of the Therapeutics Initiative, the creation of a draft which is circulated for comment among a sizeable group of over 100 local, national and international specialists with expertise in the particular therapeutic area and the commission of original artwork/illustration.
The message is developed collaboratively by different working groups of the Therapeutics Initiative. The current Editor in Chief is Dr. Tom Perry, Chair of the Education Working Group of the Therapeutics Initiative.
Therapeutics Letters on common therapies have been regularly published since 1994 and distributed free of charge to physicians and pharmacists in British Columbia to increase awareness and improve prescription habits.
The Therapeutics Letter is a member of the International Society of Drug Bulletins (ISDB), a world-wide network of independent drug bulletins that aims to promote international exchange of quality information on drugs and therapeutics.
ISSN: 2369-8691 (Online)
ISSN: 2369-8683 (Print)
